Clinical Efficacy of Ustekinumab in Crohn's Disease

Launched by KAZAKHSTAN SCIENTIFIC SOCIETY FOR STUDY OF INTESTINE DISEASES · Jul 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a medication called Ustekinumab for treating Crohn's Disease, a condition that causes inflammation in the digestive tract. The trial is currently looking for participants aged 18 and older who started using Ustekinumab between January 1 and December 31, 2024, and who can provide written agreement to take part in the study. However, there are some people who cannot join, such as those with certain serious infections, those who are pregnant or breastfeeding, and individuals with specific health issues that could complicate their participation.

If you qualify and decide to participate, you will be part of an observational study, meaning researchers will monitor your health and how well Ustekinumab works for you, without changing your treatment plan. This study aims to gather important information that could improve future treatments for Crohn’s Disease. Your involvement could help others with this condition in the future!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 years and older;
• • Patients who were first prescribed Ustekinumab between January 1 and December 31, 2024
• • Patients who provided written informed consent to participate in the study
• Exclusion Criteria:
• * Contraindications to the use of the drug Ustekinumab per the current instructions:
• • Clinically significant active infection (active tuberculosis, active viral hepatitis);
• • Pregnancy and lactation;
• • A history of clinically significant, in the opinion of the investigator, psychiatric disorders that may interfere with the study procedures and compliance with the drug regimen;
• • Ulcerative colitis;
• • Malignant gastrointestinal diseases in history or at the time of inclusion in the study;
• • Decompensated chronic diseases of the liver, kidneys, cardiovascular system, systemic vasculitis, diabetes mellitus;
• • Abuse of alcohol or psychoactive drugs within 1 year before the start of this study (as reported by the patient);
• • Participation in an interventional clinical trial.